225 related articles for article (PubMed ID: 16005220)
1. Identification of potent and selective MMP-13 inhibitors.
Wu J; Rush TS; Hotchandani R; Du X; Geck M; Collins E; Xu ZB; Skotnicki J; Levin JI; Lovering FE
Bioorg Med Chem Lett; 2005 Sep; 15(18):4105-9. PubMed ID: 16005220
[TBL] [Abstract][Full Text] [Related]
2. Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
Hu Y; Xiang JS; DiGrandi MJ; Du X; Ipek M; Laakso LM; Li J; Li W; Rush TS; Schmid J; Skotnicki JS; Tam S; Thomason JR; Wang Q; Levin JI
Bioorg Med Chem; 2005 Dec; 13(24):6629-44. PubMed ID: 16216515
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for the highly selective inhibition of MMP-13.
Engel CK; Pirard B; Schimanski S; Kirsch R; Habermann J; Klingler O; Schlotte V; Weithmann KU; Wendt KU
Chem Biol; 2005 Feb; 12(2):181-9. PubMed ID: 15734645
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.
Monovich LG; Tommasi RA; Fujimoto RA; Blancuzzi V; Clark K; Cornell WD; Doti R; Doughty J; Fang J; Farley D; Fitt J; Ganu V; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Parker DT; Melton R; O'Byrne E; Pastor G; Pellas T; Quadros E; Reel N; Roland DM; Sakane Y; Singh H; Skiles J; Somers J; Toscano K; Wigg A; Zhou S; Zhu L; Shieh WC; Xue S; McQuire LW
J Med Chem; 2009 Jun; 52(11):3523-38. PubMed ID: 19422229
[TBL] [Abstract][Full Text] [Related]
5. High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor.
Moy FJ; Chanda PK; Chen JM; Cosmi S; Edris W; Levin JI; Powers R
J Mol Biol; 2000 Sep; 302(3):671-89. PubMed ID: 10986126
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and SAR of highly selective MMP-13 inhibitors.
Li J; Rush TS; Li W; DeVincentis D; Du X; Hu Y; Thomason JR; Xiang JS; Skotnicki JS; Tam S; Cunningham KM; Chockalingam PS; Morris EA; Levin JI
Bioorg Med Chem Lett; 2005 Nov; 15(22):4961-6. PubMed ID: 16153831
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.
Esser CK; Bugianesi RL; Caldwell CG; Chapman KT; Durette PL; Girotra NN; Kopka IE; Lanza TJ; Levorse DA; MacCoss M; Owens KA; Ponpipom MM; Simeone JP; Harrison RK; Niedzwiecki L; Becker JW; Marcy AI; Axel MG; Christen AJ; McDonnell J; Moore VL; Olszewski JM; Saphos C; Visco DM; Hagmann WK
J Med Chem; 1997 Mar; 40(6):1026-40. PubMed ID: 9083493
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.
Noe MC; Natarajan V; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Otterness I; Bliven MA; Carty TJ; Barberia JT; Sweeney FJ; Liras JL; Vaughn M
Bioorg Med Chem Lett; 2005 Jul; 15(14):3385-8. PubMed ID: 15953722
[TBL] [Abstract][Full Text] [Related]
10. Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
Schnute ME; O'Brien PM; Nahra J; Morris M; Howard Roark W; Hanau CE; Ruminski PG; Scholten JA; Fletcher TR; Hamper BC; Carroll JN; Patt WC; Shieh HS; Collins B; Pavlovsky AG; Palmquist KE; Aston KW; Hitchcock J; Rogers MD; McDonald J; Johnson AR; Munie GE; Wittwer AJ; Man CF; Settle SL; Nemirovskiy O; Vickery LE; Agawal A; Dyer RD; Sunyer T
Bioorg Med Chem Lett; 2010 Jan; 20(2):576-80. PubMed ID: 20005097
[TBL] [Abstract][Full Text] [Related]
11. Pyrimidine-2,4,6-Triones: a new effective and selective class of matrix metalloproteinase inhibitors.
Grams F; Brandstetter H; D'Alò S; Geppert D; Krell HW; Leinert H; Livi V; Menta E; Oliva A; Zimmermann G; Gram F; Brandstetter H; D'Alò S; Geppert D; Krell HW; Leinert H; Livi VMenta E; Oliva A; Zimmermann G
Biol Chem; 2001 Aug; 382(8):1277-85. PubMed ID: 11592410
[TBL] [Abstract][Full Text] [Related]
12. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
[TBL] [Abstract][Full Text] [Related]
13. Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis.
Matter H; Schwab W; Barbier D; Billen G; Haase B; Neises B; Schudok M; Thorwart W; Schreuder H; Brachvogel V; Lönze P; Weithmann KU
J Med Chem; 1999 Jun; 42(11):1908-20. PubMed ID: 10354399
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.
Zhang YM; Fan X; Xiang B; Chakravarty D; Scannevin R; Burke S; Karnachi P; Rhodes K; Jackson P
Bioorg Med Chem Lett; 2006 Jun; 16(12):3096-100. PubMed ID: 16632358
[TBL] [Abstract][Full Text] [Related]
15. Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors.
Heim-Riether A; Taylor SJ; Liang S; Gao DA; Xiong Z; Michael August E; Collins BK; Farmer BT; Haverty K; Hill-Drzewi M; Junker HD; Mariana Margarit S; Moss N; Neumann T; Proudfoot JR; Keenan LS; Sekul R; Zhang Q; Li J; Farrow NA
Bioorg Med Chem Lett; 2009 Sep; 19(18):5321-4. PubMed ID: 19692239
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors.
Xu J; Wei L; Mathvink R; Edmondson SD; Mastracchio A; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Petrov A; Wu JK; Thornberry NA; Weber AE
Bioorg Med Chem Lett; 2006 Mar; 16(5):1346-9. PubMed ID: 16332437
[TBL] [Abstract][Full Text] [Related]
17. Macrocyclic amino carboxylates as selective MMP-8 inhibitors.
Cherney RJ; Wang L; Meyer DT; Xue CB; Wasserman ZR; Hardman KD; Welch PK; Covington MB; Copeland RA; Arner EC; DeGrado WF; Decicco CP
J Med Chem; 1998 May; 41(11):1749-51. PubMed ID: 9599226
[No Abstract] [Full Text] [Related]
18. Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
Cherney RJ; Mo R; Meyer DT; Hardman KD; Liu RQ; Covington MB; Qian M; Wasserman ZR; Christ DD; Trzaskos JM; Newton RC; Decicco CP
J Med Chem; 2004 Jun; 47(12):2981-3. PubMed ID: 15163180
[TBL] [Abstract][Full Text] [Related]
19. Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.
Li W; Li J; Wu Y; Rancati F; Vallese S; Raveglia L; Wu J; Hotchandani R; Fuller N; Cunningham K; Morgan P; Fish S; Krykbaev R; Xu X; Tam S; Goldman SJ; Abraham W; Williams C; Sypek J; Mansour TS
J Med Chem; 2009 Sep; 52(17):5408-19. PubMed ID: 19725580
[TBL] [Abstract][Full Text] [Related]
20. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo.
Lewis EJ; Bishop J; Bottomley KM; Bradshaw D; Brewster M; Broadhurst MJ; Brown PA; Budd JM; Elliott L; Greenham AK; Johnson WH; Nixon JS; Rose F; Sutton B; Wilson K
Br J Pharmacol; 1997 Jun; 121(3):540-6. PubMed ID: 9179398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
